Marvel Biotechnology Inc. operates in the biotechnology industry. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company targets neurological diseases that have not been treated with conventional therapeutics, such as Alzheimer's disease, depression, and addictions; lung cancer and fibrosis; and non-alcoholic steatohepatitis. Marvel Biotechnology Inc. was incorporated in 2018 and is based in Calgary, Canada.